Cyclacel Pharmaceuticals (NASDAQ:CYCC) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report report published on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Price Performance

NASDAQ:CYCC opened at $2.00 on Thursday. The business’s 50-day moving average is $2.19 and its two-hundred day moving average is $3.52. Cyclacel Pharmaceuticals has a 12 month low of $1.30 and a 12 month high of $13.20.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($6.35) by $0.12. The company had revenue of $0.03 million during the quarter. As a group, equities research analysts predict that Cyclacel Pharmaceuticals will post -18.7 EPS for the current year.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.